Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Update: 2025-10-24
Description
Featuring an interview with Dr Kevin Kalinsky, including the following topics:
- Prophylaxis, Monitoring and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (0:00 )
- Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;30(9). Abstract
- Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract
- Clinical Data with Neoadjuvant Datopotamab Deruxtecan from the I-SPY 2.2 Phase II Trial (5:17 )
- Khoury K et al. Datopotamab–deruxtecan in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med 2024;30(12):3728-36. Abstract
- Shatsky RA et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 Phase II trial. Nat Med 2024;30(12):3737-47. Abstract
- NeoSTAR: A Phase II Study of Response-Guided Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Localized Triple-Negative Breast Cancer (9:09 )
- Abelman RO et al. A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. ASCO 2025;Abstract 511.
- OptimICE-RD: A Phase III Study Evaluating Sacituzumab Govitecan with Pembrolizumab versus Pembrolizumab with or without Capecitabine for Residual Triple-Negative Breast Cancer (12:56 )
- Tolaney SM et al. OptimICE-RD: Sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncol 2024;20(31):2343-55. Abstract
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
